Pliant Therapeutics Stock Current Valuation
| PLRX Stock | USD 12.85 0.12 0.94% |
Valuation analysis of Pliant Therapeutics helps investors to measure Pliant Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to rise to about 1.1 B in 2024, whereas Enterprise Value Over EBITDA is likely to drop (6.71) in 2024. Fundamental drivers impacting Pliant Therapeutics' valuation include:
Price Book 2.2401 | Enterprise Value 430.4 M | Enterprise Value Ebitda (2.54) | Price Sales 3.1 K | Enterprise Value Revenue 1.4 K |
Undervalued
Today
Please note that Pliant Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Pliant Therapeutics is based on 3 months time horizon. Increasing Pliant Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pliant Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pliant Stock. However, Pliant Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.85 | Real 20.79 | Target 46.57 | Hype 12.85 | Naive 12.75 |
The intrinsic value of Pliant Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pliant Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pliant Therapeutics helps investors to forecast how Pliant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pliant Therapeutics more accurately as focusing exclusively on Pliant Therapeutics' fundamentals will not take into account other important factors: Pliant Therapeutics Company Current Valuation Analysis
Pliant Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pliant Therapeutics Current Valuation | 430.37 M |
Most of Pliant Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pliant Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pliant Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Pliant Therapeutics is extremely important. It helps to project a fair market value of Pliant Stock properly, considering its historical fundamentals such as Current Valuation. Since Pliant Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pliant Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pliant Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Pliant Current Valuation Historical Pattern
Today, most investors in Pliant Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pliant Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pliant Therapeutics current valuation as a starting point in their analysis.
Pliant Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pliant Therapeutics has a Current Valuation of 430.37 M. This is 97.0% lower than that of the Biotechnology sector and 90.74% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.41% higher than that of the company.
Pliant Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pliant Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pliant Therapeutics could also be used in its relative valuation, which is a method of valuing Pliant Therapeutics by comparing valuation metrics of similar companies.Pliant Therapeutics is currently under evaluation in current valuation category among its peers.
Pliant Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Pliant Therapeutics from analyzing Pliant Therapeutics' financial statements. These drivers represent accounts that assess Pliant Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pliant Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 757.2M | 807.8M | 483.9M | 812.2M | 1.1B | 1.1B | |
| Enterprise Value | 671.9M | 757.2M | 439.5M | 794.3M | 1.0B | 1.1B |
Pliant Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pliant Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pliant Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Pliant Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 430.37 M | ||||
| Shares Outstanding | 60.85 M | ||||
| Shares Owned By Insiders | 2.85 % | ||||
| Shares Owned By Institutions | 97.15 % | ||||
| Number Of Shares Shorted | 7.22 M | ||||
| Price To Book | 2.24 X | ||||
| Price To Sales | 3,050 X | ||||
| Revenue | 1.58 M | ||||
| Gross Profit | 9.69 M | ||||
| EBITDA | (158.23 M) | ||||
| Net Income | (161.34 M) | ||||
| Cash And Equivalents | 163.6 M | ||||
| Cash Per Share | 3.36 X | ||||
| Total Debt | 11.37 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 7.69 X | ||||
| Book Value Per Share | 5.68 X | ||||
| Cash Flow From Operations | (116.36 M) | ||||
| Short Ratio | 17.04 X | ||||
| Earnings Per Share | (3.35) X | ||||
| Target Price | 40.18 | ||||
| Number Of Employees | 166 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 781.97 M | ||||
| Total Asset | 512.15 M | ||||
| Retained Earnings | (499.75 M) | ||||
| Working Capital | 476.98 M | ||||
| Net Asset | 512.15 M |
About Pliant Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pliant Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pliant Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pliant Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.